Babette Dieringer

miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas

Ahmet Hazini, Babette Dieringer, Markian Pryshliak et al. · Human Gene Therapy · 2021 · 27 citations

Life Sciences, Molecular Biology, Oncology +16

Early Treatment of Coxsackievirus B3–Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy

Sandra Pinkert, Babette Dieringer, Robert Klopfleisch et al. · Circulation Heart Failure · 2019 · 25 citations

Life Sciences, Cardiology, Pharmacology +15

Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas

Sandra Pinkert, Markian Pryshliak, Kathleen Pappritz et al. · Cardiovascular Research · 2019 · 24 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +15

Cerebral blood volume estimation by ferumoxytol‐enhanced steady‐state MRI at 9.4 T reveals microvascular impact of α₁‐adrenergic receptor antibodies

Andreas Pohlmann, Peter Karczewski, Min‐Chi Ku et al. · NMR in Biomedicine · 2014 · 18 citations

Medicine, Neurology, Neuroscience +17

Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus

Sandra Pinkert, Babette Dieringer, Sabine Diedrich et al. · Antiviral Research · 2016 · 16 citations

Life Sciences, Infectious Diseases, Pharmacology +16